Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
October 27, 2015 08:30 ET
|
Quark Pharmaceuticals, Inc. USA.
FREMONT, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company, who is a leader in the discovery and development of novel RNA interference...
Quark Pharmaceuticals Reports Favorable Results From Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002
July 28, 2014 11:00 ET
|
Quark Pharmaceuticals, Inc. USA.
Data on siRNA for the Prophylaxis of Delayed Graft Function in Deceased Donor Kidney Transplant Patients Presented at World Transplant Congress
Proof of Concept for First-in-Class Systemically...
Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients
July 01, 2014 08:34 ET
|
Quark Pharmaceuticals, Inc. USA.
FREMONT, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc. today reported completion of a randomized, placebo-controlled multicenter Phase II trial of QPI-1002 for the prophylaxis...
Quark Announces First Patient Dosed in a Phase IIa Trial Evaluating QPI-1007 for Neuroprotection in Patients With Acute Primary Angle Closure Glaucoma
June 25, 2014 09:48 ET
|
Quark Pharmaceuticals, Inc. USA.
FREMONT, Calif., June 25, 2014 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc. today announced that the first patient has been dosed in a double-masked, randomized sham controlled Phase IIa safety,...
Quark Pharmaceuticals and Suzhou Ribo Life Science Raise Nearly RMB 45 Million for Newly Established Chinese Joint Venture
January 07, 2014 08:01 ET
|
Quark Pharmaceuticals, Inc. USA.
KUNSHAN, China, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. ("RiboQuark"), a Chinese-foreign equity joint venture and clinical stage pharmaceutical company,...
Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA Based Therapeutics
December 18, 2013 08:00 ET
|
Quark Pharmaceuticals, Inc. USA.
BANGALORE, India and FREMONT, Calif., Dec. 18, 2013 (GLOBE NEWSWIRE) -- Biocon Ltd, Asia's premier biotechnology company, and Quark Pharmaceuticals, Inc., a world leader in the discovery and...
Quark Pharmaceuticals Announces Phase 2a Study of PF--04523655 (PF-655) in Patients With Moderate and Advanced Open-Angle Glaucoma (OAG)
May 01, 2012 08:00 ET
|
Quark Pharmaceuticals, Inc. USA.
FREMONT, Calif., May 1, 2012 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc., today announced that Quark and Pfizer have amended their existing exclusive Licensing Agreement in order to enable Quark...